Charles River Laboratories International, Inc. (CRL) Stock Score, Valuation & Financial Research
Charles River Laboratories International, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for CRL
Charles River Laboratories International, Inc. currently has a Wall Street Score of 26/100. The stored market price is $273.41. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Charles River Laboratories International, Inc. does
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models
CRL financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $273.41
- Market capitalization:
- $13.17B
- Revenue:
- $4.00B
- Net income:
- $-238.5M
- Free cash flow:
- $518.5M
- Cash:
- $192.0M
- Total debt:
- $3.03B
- EPS:
- -4.84
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 3/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $518.5M, showing positive cash generation.
- The balance sheet shows $192.0M of cash versus $3.03B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CRL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.